Product Profiles: Depression - Next generation vies for second-line patients

Introduction

Patents for the current market-leading depression brands are due to expire in the major markets between 2012 and 2015, by which time competition in the market will be at its fiercest. In order to flourish in this harsh environment, new antidepressants must be sufficiently differentiated from conventional monoamine neurotransmitter reuptake inhibitors.

Features and benefits

* Understand Datamonitor’s independent appraisal of marketed brands and key pipeline agents indicated for treating depression.
* Illustrate how pipeline and marketed drugs compare to one another in terms of clinical and commercial attributes.
* Review important clinical developments for key pipeline agents with analysis of the latest clinical trial data.
* Understand how marketed brands are positioned in the depression treatment algorithm and how they are perceived by psychiatrists.
* Determine to what extent future therapies satisfy the main clinical unmet needs in depression treatment.

Highlights

Datamonitor’s physician survey reveals that psychiatrists perceive Forest’s and Lundbeck’s selective serotonin reuptake inhibitor Lexapro (escitalopram) to be the leading depression treatment, with a superior efficacy and tolerability profile to other antidepressant brands.
Valdoxan (agomelatine; Servier/Novartis) and several pipeline antidepressants are poised to usurp Lexapro, following its loss of market exclusivity, and become the most attractive depression brands.
Forest’s Viibryd (vilazodone) has the hallmarks of a new blockbuster – a novel mode of action, favorable tolerability, and the marketing prowess of Forest. Viibryd will be well received due to its good tolerability, although commercial success comparable to Lexapro will be unattainable as more innovative competitor drugs near the US market.

Your key questions answered

* What is the gold-standard drug for depression?
* How are marketed brands positioned in the depression treatment algorithm?
* Which are the most likely drugs to emerge from the pipeline and how will they impact the way depression is treated?
* What are the comparative strengths and weaknesses of the key depression brands and pipeline candidates?
[Studien Infos ausblenden]

Executive Summary
Strategic scoping and focus
Datamonitor key findings
Related reports
OVERVIEW
Catalyst
Summary
MARKET DEFINITION AND OVERVIEW
Product overview
MARKETED PRODUCT PROFILES
Lexapro (escitalopram; Forest/Lundbeck)
Drug profile
Development overview
SWOT analysis
Product positioning
Physicians' perceptions of Lexapro
Clinical and commercial attractiveness
Effexor XR (venlafaxine extended release; Pfizer)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Pristiq (desvenlafaxine; Pfizer)
Drug profile
Development overview
SWOT analysis
Product positioning
Physicians' perceptions of Pristiq
Clinical and commercial attractiveness
Cymbalta (duloxetine; Eli Lilly/Shionogi)
Drug profile
Development overview
SWOT analysis
Product positioning
Physicians' perceptions of Cymbalta
Clinical and commercial attractiveness
Valdoxan (agomelatine; Servier/Novartis)
Drug profile
Development overview
SWOT analysis
Product positioning
Physicians' perceptions of Valdoxan
Clinical and commercial attractiveness
Abilify (aripiprazole; Bristol-Myers Squibb/Otsuka)
Drug profile
Development overview
SWOT analysis
Product positioning
Physicians' perceptions of Abilify
Clinical and commercial attractiveness
Seroquel XR (quetiapine extended release; AstraZeneca)
Drug profile
Development overview
SWOT analysis
Product positioning
Physicians' perceptions of Seroquel XR
Clinical and commercial attractiveness
Oleptro (trazodone extended release; Labopharm)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Other marketed drugs for depression
Remeron (mirtazapine; Merck & Co./Meiji Seika)
PIPELINE PRODUCT PROFILES
Viibryd (vilazodone; Forest)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Lu AA21004 (Lundbeck/Takeda)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
TC-5214 (Targacept/AstraZeneca)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Levomilnacipran (F2695; Forest/Pierre Fabre)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Edivoxetine (LY2216684; Eli Lilly)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Vyvanse (lisdexamfetamine; Shire)
Drug profile
Development overview
SWOT analysis
Satisfaction of unmet needs
Clinical and commercial attractiveness
Other drugs in development for depression
CPI-300 (bupropion; IntelGenx)
AZD6765 (AstraZeneca)
BCI-224 (sabcomeline; BrainCells)
BCI-540 (coluracetam; BrainCells/Mitsubishi Tanabe)
BCI-952 (melatonin and buspirone; Brain Cells)
BMS-820836 (Bristol-Myers Squibb/AMRI)
Cariprazine (RGH-118; Forest/Gedeon Richter/Mitsubishi Tanabe)
Cimicoxib (UR-8880; Affectis Pharmaceuticals/Palau Pharma)
CP-601,927 (Pfizer)
EB-1010 (Euthymics Bioscience)
GLYX-13 (Naurex)
JNJ-26489112 (Johnson & Johnson)
Lu AA24530 (Lundbeck/Takeda)
OPC-34712 (Otsuka)
Orvepitant (GSK823296; GlaxoSmithKline)
PNB-01 (pipamperone and citalopram; PharmaNeuroBoost)
RG7090 (Roche)
SA4503 (cutamesine; M’s Science)
Serdaxin (clavulanic acid; Rexahn Pharmaceuticals)
SSR125543 (Sanofi)
Tasimelteon (VEC-162; Vanda Pharmaceuticals)
TriRima (CX157; CeNeRx/Krenitsky Pharmaceuticals)
BIBLIOGRAPHY
Journal papers
Websites
Datamonitor reports
APPENDIX A – SURVEY INFORMATION
Physician research methodology
Physician sample breakdown
The survey questionnaire
Introduction
Section one: diagnosis and patient segmentation
Section two: treatment of major depressive disorder
Section three: product profiles
Demographics
APPENDIX B
PharmaVitae Explorer database
Contributing experts
Conferences attended
Report methodology
[Inhaltsverzeichnis ausblenden]